Interventional, Open Label, Reduced/Staged, Single Dose Study Investigating the Pharmacokinetic Properties of Lu AF35700 in Subjects With Renal Impairment and in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 19 Jun 2018
At a glance
- Drugs LU AF-35700 (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Lundbeck A/S
- 12 Jun 2018 Planned End Date changed from 1 May 2018 to 1 Oct 2018.
- 12 Jun 2018 Planned primary completion date changed from 1 May 2018 to 1 Oct 2018.
- 09 Aug 2017 New trial record